Markets:

Overview

News

Currencies

International

Treasuries

Alpha Cognition Inc. - Common Stock (NQ:ACOG)

9.000 +0.300 (+3.45%)

Delayed Quote Updated: 10:21 AM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Alpha Cognition Inc. - Common Stock

Alpha Cognition (ACOG) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

ZUNVEYL revenue surged 71% sequentially as repeat prescriber rates hit 76%.

Via The Motley Fool

Topics Earnings

Alpha Cognition Q2 Earnings Call Highlights ↗

August 13, 2026

Alpha Cognition (NASDAQ:ACOG) reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer’s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the...

Via MarketBeat

Topics Earnings

Alpha Cognition Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Alpha Cognition (NASDAQ:ACOG) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by...

Via Benzinga

Topics Earnings

Alpha Cognition Q1 Earnings Call Highlights ↗

May 14, 2026

Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across...

Via MarketBeat

Topics Earnings

Alpha Cognition (NASDAQ:ACOG) Q1 Revenue Meets Estimates as Commercial Momentum Builds ↗

May 14, 2026

Via Chartmill

Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q4 Revenue Miss Amid Strong Alzheimer's Drug Launch ↗

March 26, 2026

Via Chartmill

Alpha Cognition (ACOG) Q1 2026 Earnings Transcript ↗

May 14, 2026

Alpha Cognition (ACOG) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Alpha Cognition (ACOG) Q4 2025 Earnings Transcript ↗

April 01, 2026

Alpha Cognition (ACOG) Q4 2025 Earnings Transcript

Via The Motley Fool

Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year ↗

March 15, 2026

This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.

Via The Motley Fool

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue ↗

March 15, 2026

Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.

Via The Motley Fool

Solas Capital Loads Up On Kyndryl With 407,000 Shares Bought ↗

March 05, 2026

This technology firm delivers IT infrastructure and managed solutions to major enterprises across multiple global industries.

Via The Motley Fool

Topics Artificial Intelligence

Alpha Cognition Inc. (NASDAQ:ACOG) Reports Q3 2025 Revenue Beat and Strong Commercial Progress for ZUNVEYL ↗

November 13, 2025

Alpha Cognition's Q3 2025 results beat revenue estimates by 37% on strong sales of its Alzheimer's drug, ZUNVEYL, showing significant commercial momentum.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 30, 2025

Via Benzinga

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

April 24, 2025

Via Benzinga

Earnings Scheduled For March 31, 2025 ↗

March 31, 2025

Via Benzinga

Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst ↗

March 18, 2025

HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.

Via Benzinga

This West Pharmaceutical Services Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

March 18, 2025

Via Benzinga

Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China ↗

January 08, 2025

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits for blast-related brain injuries.

Via Benzinga

Invizyne Technologies Jumps After IPO ↗

November 17, 2024

Invizyne Technologies opened on Nov. 13 at $11.10. Shares gained as much as 13% following the company's $15 million initial public offering. Additionally, Alpha Cognition opened on Nov. 12 at $7.00.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.